■微粉化的纯化类黄酮部分(MPFF)是一种广泛处方和广泛研究的静脉活性药物(VAD)。MPFF的标准剂量为500mg,每天两次给药。然而,刚刚推出了新的每日剂量1000毫克。
■这项研究调查了公众是否可以实施和接受1000mgMPFF的每日剂量,并且仍然具有与常规药物相同的治疗效果。
■对于此荟萃分析,我们搜索了MEDLINE,Embase,Web科学,科克伦,和PubMed数据库以及在数据库开始至2023年3月之间发表的研究的前向和后向引用。纳入3个随机对照试验(RCT),比较不同剂量的MPFF,以评价它们之间是否有显著性差异,没有语言或日期限制。由于纳入的研究样本量小,我们使用一对一的排除法进行了简单的敏感性测试,结果表明,该研究并未影响最终的合并结论。使用Cochrane偏差风险工具评估证据的质量。
■在232项研究中,99个符合条件,39个RCT有数据,都有低到中等的偏差。总的来说,1924例患者(实验组:967,对照组:957)在3项随机对照试验中符合该标准。患者依从性无显著差异,功效,临床不良事件,每天一次的MPFF1000mg和每天两次的MPFF500mg之间的生活质量评分(标准化平均差[SMD]:0.049[0.048,0.145],p=0.321,风险比[RR]:0.981[0.855,1.125],p=0.904,SMD:0.063[0.034,0.160],p=0.203)。
■在有症状的慢性静脉疾病患者中,MPFF1000毫克每日一次和MPFF500毫克每日两次改善患者的依从性,下肢不适,临床不良事件,和生活质量得分相似。定期医疗应建议MPFF每天1000毫克更频繁。
结论:微粉化纯化黄酮类成分(MPFF)是现代医学中一种流行的静脉活性药物(VAD)。MPFF可有效治疗下肢静脉问题。目前,除了常规的500毫克片剂,存在替代剂型,如溶液,咀嚼片,和其他用于MPFF的新型配方。药物的过度频率和数量可能对患者依从性产生负面影响。
UNASSIGNED: Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced.
UNASSIGNED: This study investigated whether a daily dose of 1000 mg MPFF could be implemented and embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals.
UNASSIGNED: For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool.
UNASSIGNED: Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimental group: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, and SMD: 0.063 [0.034, 0.160], p=0.203).
UNASSIGNED: In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.
CONCLUSIONS: Micronized purified flavonoid fraction (MPFF) is a popular venoactive medication (VAD) in modern medicine.MPFF is effective in treating lower extremity venous problems.Currently, besides conventional 500 mg tablets, there exist alternative dosage forms such as solutions, chewable tablets, and other novel formulations for MPFF.The excessive frequency and amount of medication may have a negative impact on patient adherence.